Drug development advances in beneficial loss-of-function mutation targets validated by human genetics

Drug targets with human genetic evidence are more likely than those without to be clinically translatable and thus enter phase II/III clinical trials or be approved for marketing more quickly, which will likely significantly reduce the cost of drug development and drive the rapid development of the pharmaceutical industry.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup